Eisai/Biogen’s Lecanemab Faces Smoother Passage Through US FDA Than Aducanumb

 
• By Sue Sutter
Smooth sailing
The regulatory sailing should be smoother for Eisai/Biogen's second-in-class amyloid-targeted antibody lecanemab. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet